Our preliminary results confirmed the impact of IGF2BP1 on the clinical prognosis of HCC patients and the CD8+ T infiltration immune microenvironment, indicating that IGF2BP1 could potentially control the anti-tumor immunity of CD8+ T cells within the HCC microenvironment. The gene discussed is IGF2BP1; the disease is hepatocellular carcinoma.